Article
Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients.
International journal of molecular sciences - 18 Jan 2023
Sokolenko Anna P, Moiseyenko Fedor V, Iyevleva Aglaya G, Ivantsov Alexandr O, Dolmatov Georgiy D, Shelekhova Ksenia V, Gulo Elizaveta V, Topal Anastasya X, Artemieva Elizaveta V, Abduloeva Nuriniso H, Rysev Nikita A, Barsova Daria A, Levchenko Natalia V, Volkov Nikita M, Egorenkov Vitaliy V, Moiseyenko Vladimir M, Imyanitov Evgeny N
Abstract excerpt
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcinomas arising in BRCA1 mutation carriers almost always carry alterations of the TP53 gene thus providing an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.